-
Methodological challenges in the development of endpoints for myelofibrosis clinical trials Lancet Haematol. (IF 24.7) Pub Date : 2024-04-08 Giovanni Barosi MD, Ayalew Tefferi MD, Naseema Gangat MD, Natasha Szuber MD, Prof Alessandro Rambaldi MD, Olatoyosi Odenike MD, Nicolaus Kröger MD, Nico Gagelmann MD, Moshe Talpaz MD, Hagop Kantarjian MD, Robert Peter Gale MD
Myelofibrosis is a myeloid neoplasm characterised by the presence of , or mutations (with a 90% mutation frequency) and trilineage myeloid proliferation with prominent megakaryocyte atypia. People with myelofibrosis have a lower survival rate and poorer quality of life than healthy individuals. Therapy for myelofibrosis uses Janus kinase inhibitors, which reduce splenomegaly and alleviate symptoms
-
Transplant without salvage: cut out the middleman Lancet Haematol. (IF 24.7) Pub Date : 2024-04-04 Arjun Datt Law, Jonas Ingemar Mattsson
-
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial Lancet Haematol. (IF 24.7) Pub Date : 2024-04-04 Prof Matthias Stelljes MD, Jan Moritz Middeke MD, Gesine Bug MD, Eva-Maria Wagner-Drouet MD, Prof Lutz P Müller MD, Prof Christoph Schmid MD, Prof Stefan W Krause MD, Prof Wolfgang Bethge MD, Prof Edgar Jost MD, Prof Uwe Platzbecker MD, Stefan A Klein MD, Prof Jörg Schubert MD, Judith Niederland MD, Martin Kaufmann MD, Kerstin Schäfer-Eckart MD, Prof Markus Schaich MD, Henning Baldauf MSc, Prof Friedrich
Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear. To test salvage chemotherapy before allogeneic HSCT, patients aged between 18 and 75 years
-
The value of anti-CD30 CAR T cells in Hodgkin lymphoma Lancet Haematol. (IF 24.7) Pub Date : 2024-03-28 Marianne Veyri
-
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study Lancet Haematol. (IF 24.7) Pub Date : 2024-03-28 Natalie S Grover MD, George Hucks MD, Marcie L Riches MD, Prof Anastasia Ivanova PhD, Dominic T Moore MPH, Prof Thomas C Shea MD, Mary Beth Seegars MD, Paul M Armistead MD, Prof Kimberly A Kasow DO, Anne W Beaven MD, Christopher Dittus DO, James M Coghill MD, Katarzyna J Jamieson MD, Benjamin G Vincent MD, Prof William A Wood MD, Catherine Cheng BS, Julia Kaitlin Morrison PhD, John West PhD, Tammy
Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have promising activity when preceded by lymphodepleting chemotherapy. We aimed to determine the safety of anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation (HSCT) in patients with CD30 lymphoma at high risk of relapse. This phase 1 dose-escalation study was performed at two sites in the
-
Riociguat shows remarkable safety but underwhelming activity in patients with sickle cell disease Lancet Haematol. (IF 24.7) Pub Date : 2024-03-27 Emily M Limerick, Courtney D Fitzhugh
-
First-line immunochemotherapy for extranodal natural killer/T cell lymphoma Lancet Haematol. (IF 24.7) Pub Date : 2024-03-27 Shu-Nan Qi, Ye-Xiong Li
-
First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial Lancet Haematol. (IF 24.7) Pub Date : 2024-03-27 Prof Xiao-Peng Tian MD, Jun Cai MD, Prof Yi Xia MD, Yu-Chen Zhang MD, Prof Liang Wang MD, Pan-Pan Liu MD, Prof Hui-Qiang Huang MD, Prof Ya-Jun Li MD, Prof Hui Zhou MD, Zhi-Ming Li MD, Jing Yang MD, Li-Qiang Wei MD, Qi-Hua Zou MD, Prof Ying Huang MD, Prof Jun Li PhD, Prof Li Ling PhD, Prof Wen-Long Zhong MD, Qing-Qing Cai MD
Programmed cell death protein 1 (PD-1) inhibitor sintilimab is effective in relapsed and refractory extranodal natural killer/T cell lymphoma (ENKTL), nasal type. We aimed to assess the safety and activity of sintilimab plus P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) in the first-line setting for advanced ENKTL. The multicentre, single-arm, phase 2 trial was done at three medical centres
-
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial Lancet Haematol. (IF 24.7) Pub Date : 2024-03-27 Prof Mark T Gladwin MD, Prof Victor R Gordeuk MD, Payal C Desai MD, Prof Caterina Minniti MD, Enrico M Novelli MD, Prof Claudia R Morris MD, Prof Kenneth I Ataga MD, Prof Laura De Castro MD, Susanna A Curtis MD, Fuad El Rassi MD, Prof Hubert James Ford MD, Thomas Harrington MD, Prof Elizabeth S Klings MD, Prof Sophie Lanzkron MD, Prof Darla Liles MD, Prof Jane Little MD, Alecia Nero MD, Prof Wally
Although nitric oxide based therapeutics have been shown in preclinical models to reduce vaso-occlusive events and improve cardiovascular function, a clinical trial of a phosphodiesterase 5 inhibitor increased rates of admission to hospital for pain. We aimed to examine if riociguat, a direct stimulator of the nitric oxide receptor soluble guanylate cyclase, causes similar increases in vaso-occlusive
-
Sex and gender reporting advances in medicine Lancet Haematol. (IF 24.7) Pub Date : 2024-03-07 The Lancet Haematology
-
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia Lancet Haematol. (IF 24.7) Pub Date : 2024-03-04 Anna Candoni
-
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study Lancet Haematol. (IF 24.7) Pub Date : 2024-03-04 Alexandre Bazinet MD, Prof Guillermo Garcia-Manero MD, Nicholas Short MD, Yesid Alvarado MD, Alex Bataller MD, Tareq Abuasab MD, Rabiul Islam MD, Kathryn Montalbano RN, Ghayas Issa MD, Abhishek Maiti MD, Musa Yilmaz MD, Prof Nitin Jain MD, Lucia Masarova MD, Prof Steven Kornblau MD, Prof Elias Jabbour MD, Guillermo Montalban-Bravo MD, Caitlin R Rausch PharmD, Sherry Pierce RN, Prof Courtney D DiNardo
Hypomethylating agents combined with venetoclax are effective regimens in patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy. Decitabine and cedazuridine (ASTX727) is an oral formulation of decitabine that achieves equivalent area-under-curve exposure to intravenous decitabine. We performed a single centre phase 2 study to evaluate the efficacy and safety of ASTX727
-
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond Lancet Haematol. (IF 24.7) Pub Date : 2024-03-01 Margareth C Ozelo
-
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial Lancet Haematol. (IF 24.7) Pub Date : 2024-03-01 Michiel Coppens MD, Prof Steven W Pipe MD, Prof Wolfgang Miesbach MD, Prof Jan Astermark MD, Michael Recht MD, Paul van der Valk MD, Bruce Ewenstein MD, Karen Pinachyan MD, Nicholas Galante PhD, Sandra Le Quellec MD, Prof Paul E Monahan MD, Prof Frank W G Leebeek MD, HOPE-B Investigators, Giancarlo Castaman, Shelley E Crary, Miguel Escobar, Esteban Gomez, Kristina M Haley, Cedric R J R Hermans, Peter
Etranacogene dezaparvovec, the first gene therapy approved for haemophilia B treatment, was shown to be superior to treatment with continuous prophylactic factor IX in terms of bleeding protection 18 months after gene therapy in a phase 3 trial. We report post-hoc 24-month efficacy and safety data from this trial to evaluate the longer-term effects of etranacogene dezaparvovec in individuals with haemophilia
-
Defining global thresholds for anaemia: a challenging mission Lancet Haematol. (IF 24.7) Pub Date : 2024-02-29 Jahnavi Daru, Javier Zamora
-
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources Lancet Haematol. (IF 24.7) Pub Date : 2024-02-29 Sabine Braat MSc, Katherine L Fielding MBBS, Jiru Han PhD, Victoria E Jackson PhD, Sophie Zaloumis PhD, Jessica Xu Hui Xu MBiostat, Gemma Moir-Meyer PhD, Sophia M Blaauwendraad MD, Prof Vincent W V Jaddoe PhD, Romy Gaillard PhD, Patricia C Parkin MD, Cornelia M Borkhoff PhD, Charles D G Keown-Stoneman PhD, Prof Catherine S Birken MD, Jonathon L Maguire MD, Genes & Health Research Team, Prof Melanie
Detection of anaemia is crucial for clinical medicine and public health. Current WHO anaemia definitions are based on statistical thresholds (fifth centiles) set more than 50 years ago. We sought to establish evidence for the statistical haemoglobin thresholds for anaemia that can be applied globally and inform WHO and clinical guidelines. In this analysis we identified international data sources from
-
Models of care for sickle cell disease in low-income and lower-middle-income countries: a scoping review Lancet Haematol. (IF 24.7) Pub Date : 2024-02-29 Laura Drown MPH, Miriam Osei MD, Ada Thapa MPH, Chantelle Boudreaux ScD, Natasha Archer MD, Gene Bukhman MD, Alma J Adler PhD
Sickle cell disease has a growing global burden falling primarily on low-income countries (LICs) and lower-middle-income countries (LMICs) where comprehensive care is often insufficient, particularly in rural areas. Integrated care models might be beneficial for improving access to care in areas with human resource and infrastructure constraints. As part of the Centre for Integration Science's ongoing
-
A thank you to our 2023 reviewers and update on inclusion and diversity commitments Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 The Editors of The Lancet Haematology
-
Health-care transition services for sickle cell disease in Brazil Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Jane S Hankins, Clarisse Lobo, Josefina A P Braga, Tarun Aurora, Kelly Pimenta, Maria Stella Figueiredo, Ana A Baumann
-
Gender composition and geographical representation of American Society of Hematology clinical practice guideline authors Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Jeremy W Jacobs, Amarilis A Martin, Laura D Stephens, Brian D Adkins, Jennifer S Woo, Deva Sharma, Allison P Wheeler, Raeshun T Glover, Jennifer C Yui, Shannon C Walker, Shazia S Khan, Garrett S Booth, Julie K Silver
-
Thank you to The Lancet Haematology's peer reviewers in 2023 Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 The Lancet Haematology Editors
-
Celebrating our community: a call for essays and art Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 The Editors of The Lancet Haematology
-
Balancing the risks and benefits of CAR T-cell therapy Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 The Lancet Haematology
-
Clinical implications and insights from patient-reported outcome data in KarMMa-3 Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Rajshekhar Chakraborty
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Prof Michel Delforge MD, Krina Patel MD, Laurie Eliason MPH, Devender Dhanda PhD, Ling Shi PhD, Shien Guo PhD, Thomas S Marshall PharmD, Prof Bertrand Arnulf MD, Prof Michele Cavo MD, Prof Ajay Nooka MD, Salomon Manier MD, Natalie Callander MD, Sergio Giralt MD, Prof Hermann Einsele MD, Prof Sikander Ailawadhi MD, Mihaela Popa McKiver MD PhD, Mark Cook MBChB PhD, Paula Rodríguez-Otero MD
Chimeric antigen receptor T-cell therapy idecabtagene vicleucel (ide-cel) showed significantly improved progression-free survival compared with standard regimens in adults with relapsed and refractory multiple myeloma who had received two to four previous regimens in the ongoing phase 3 KarMMa-3 trial (). This study analysed patient-reported outcomes (PROs), a KarMMa-3 secondary endpoint. In the randomised
-
Thrombotic complications of immune thrombocytopenic purpura Lancet Haematol. (IF 24.7) Pub Date : 2024-02-27 Philip Qian MD, Abbey Willcox MBBS, Edward R Scheffer Cliff MBBS
-
-
-
Activity and safety of eltrombopag in combination with cyclosporin A as first‑line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study Lancet Haematol. (IF 24.7) Pub Date : 2024-02-06 Phillip Scheinberg MD PhD, Carlo Finelli MD, Efreen H Montaňo-Figueroa MD, Carlos Vallejo MD, Lalita Norasetthada MD, Prof Rodrigo T Calado MD, Prof Mehmet Turgut MD, Prof Régis Peffault de Latour MD, Ulrike Kriemler-Krahn BA, Jens Haenig PhD, Joan Clark MSc, Prof Junho Jang MD
Antithymocyte globulin (ATG)-based immunosuppression is standard in front-line treatment for people with severe aplastic anaemia without a histocompatible donor or who are 40 years or older. However, ATG requires in-hospital administration, is associated with infusion-related toxicities and has limited availability worldwide. In this study, we investigated the activity and safety of an ATG-free regimen
-
Consideration of ATG-free therapy with eltrombopag and cyclosporine for severe aplastic anaemia Lancet Haematol. (IF 24.7) Pub Date : 2024-02-06 Emma M Groarke
-
Correction to Lancet Haematol 2024; 11: e38–50 Lancet Haematol. (IF 24.7) Pub Date : 2024-02-05
Abstract not available
-
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines Lancet Haematol. (IF 24.7) Pub Date : 2024-02-05 Hanny Al-Samkari MD, Prof Nadine Shehata MD MSc, Kelly Lang-Robertson MLIS, Paola Bianchi PhD, Andreas Glenthøj MD PhD, Prof Sujit Sheth MD, Prof Ellis J Neufeld MD PhD, Prof David C Rees MBBS, Satheesh Chonat MD, Kevin H M Kuo MD MSc, Prof Jennifer A Rothman MD, Prof Wilma Barcellini MD, Eduard J van Beers MD PhD, Dagmar Pospíšilová MD PhD, Prof Ami J Shah MD, Richard van Wijk PhD, Prof Bertil Glader
Pyruvate kinase (PK) deficiency is the most common cause of chronic congenital non-spherocytic haemolytic anaemia worldwide, with an estimated prevalence of one in 100 000 to one in 300 000 people. PK deficiency results in chronic haemolytic anaemia, with wide ranging and serious consequences affecting health, quality of life, and mortality. The goal of the International Guidelines for the Diagnosis
-
Lallindra Gooneratne—maintaining treatment flow amid crisis Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Ray Cavanaugh
Abstract not available
-
Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia Lancet Haematol. (IF 24.7) Pub Date : 2024-02-02 Sarit Assouline
Abstract not available
-
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study Lancet Haematol. (IF 24.7) Pub Date : 2024-02-02 Alex Bataller MD, Guillermo Montalban-Bravo MD, Alexandre Bazinet MD, Yesid Alvarado MD, Kelly Chien MD, Sangeetha Venugopal MD, Jo Ishizawa MD, Danielle Hammond MD, Mahesh Swaminathan MD, Koji Sasaki MD, Ghayas C Issa MD, Nicholas J Short MD, Lucia Masarova MD, Prof Naval G Daver MD, Prof Tapan M Kadia MD, Simona Colla PhD, Wei Qiao PhD, Prof Xuelin Huang PhD, Rashmi Kanagal-Shamanna MD, Stephany
Hypomethylating agents are approved in higher-riskmyelodysplastic syndromes. The combination of a hypomethylating agent with venetoclax is standard of care in acute myeloid leukaemia. We investigated the safety and activity of the first totally oral combination of decitabine plus cedazuridine and venetoclax in patients with higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia
-
Production and supply of blood products in Brazil Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Tony Kirby
Abstract not available
-
Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Pauline Hägele, Paulina Staus, Raphael Scheible, Annette Uhlmann, Maximilian Heeg, Christian Klemann, Maria Elena Maccari, Henrike Ritterbusch, Martin Armstrong, Ioana Cutcutache, Katherine S Elliott, Horst von Bernuth, Timothy Ronan Leahy, Jörg Leyh, Dirk Holzinger, Kai Lehmberg, Peter Svec, Katja Masjosthusmann, Sophie Hambleton, Marcus Jakob, Thomas Wiesel
Background Lymphoproliferation and autoimmune cytopenias characterise autoimmune lymphoproliferative syndrome. Other conditions sharing these manifestations have been termed autoimmune lymphoproliferative syndrome-like diseases, although they are frequently more severe. The aim of this study was to define the genetic, clinical, and immunological features of these disorders to improve their diagnostic
-
Improving equity for people living with rare diseases Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30
Abstract not available
-
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Hideto Tamura
Abstract not available
-
Prospective characterisation of non-malignant, paediatric lymphoproliferative disease Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Troy R Torgerson
Abstract not available
-
Advancements in haemophilia A and health equity: is it time to redefine severity? Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Angela C Weyand, Lynn Malec, Steven W Pipe
Abstract not available
-
A treatise on clinical trials Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Talal Hilal
Abstract not available
-
Acute promyelocytic leukaemia in low-income and middle-income countries: a Brazilian experience Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Diego A Pereira-Martins, Isabel Weinhäuser, Juan L Coelho-Silva, Emanuele Ammatuna, Gerwin Huls, Jan Jacob Schuringa, Eduardo M Rego, Antonio R Lucena-Araujo
Abstract not available
-
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Elias K Mai, Hartmut Goldschmid, Kaya Miah, Uta Bertsch, Britta Besemer, Mathias Hänel, Julia Krzykalla, Roland Fenk, Jana Schlenzka, Markus Munder, Jan Dürig, Igor W Blau, Stefanie Huhn, Dirk Hose, Anna Jauch, Christina Kunz, Christoph Mann, Niels Weinhold, Christof Scheid, Roland Schroers, Iris Zirpel
Background The aim of this trial was to investigate the addition of the anti-SLAMF7 monoclonal antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) in induction and consolidation therapy as well as to lenalidomide maintenance treatment in transplant-eligible patients with newly diagnosed multiple myeloma. Methods GMMG-HD6 was a phase 3, randomised trial conducted at 43 main trial
-
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Valentin Lacombe, Jérome Hadjadj, Sophie Georgin-Lavialle, Christian Lavigne, Franck Geneviève, Olivier Kosmider
The presence of vacuoles in myeloid and erythroid progenitor cells in bone marrow aspirates is a key feature of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. The mere observation of vacuolated progenitor cells is not specific to VEXAS syndrome; in this Viewpoint, we point out the causes to be considered in this situation. Vacuoles, in particular, can be observed in individuals
-
When cancer disguises: small-cell lung cancer masquerading as HIV-associated lymphoma in leukaemic phase Lancet Haematol. (IF 24.7) Pub Date : 2024-01-30 Shuhei Kurosawa, Yusuke Hamakawa, Yukihiro Yoshimura, Hiroyuki Hayashi, Tomonori Nakazato, Hiroaki Okamoto
Abstract not available
-
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial Lancet Haematol. (IF 24.7) Pub Date : 2024-01-29 Elisabeth Schorb MD, Lisa Kristina Isbell MD, Andrea Kerkhoff MD, Prof Stephan Mathas MD, Friederike Braulke PhD, Gerlinde Egerer MD, Alexander Röth MD, Simon Schliffke MD, Peter Borchmann MD, Uta Brunnberg MD, Frank Kroschinsky MBA, Robert Möhle MD, Andreas Rank MD, Dominique Wellnitz MD, Benjamin Kasenda PhD, Lisa Pospiech MD, Julia Wendler MD, Florian Scherer MD, Prof Martina Deckert MD, Elina Henkes
Available treatments for older patients with primary diffuse large B-cell CNS lymphoma (PCNSL) offer progression-free survival of up to 16 months. We aimed to investigate an intensified treatment of high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT) in older patients with PCNSL. MARTA was a prospective, single-arm, phase 2 study done at 15 research hospitals in Germany
-
Extending potentially curative options for older patients with PCNSL Lancet Haematol. (IF 24.7) Pub Date : 2024-01-29 Elizabeth H Phillips, Kate Cwynarski
Abstract not available
-
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study Lancet Haematol. (IF 24.7) Pub Date : 2024-01-05 Pau Abrisqueta, Eva González-Barca, Carlos Panizo, José María Arguiñano Pérez, Fiona Miall, Mariana Bastos-Oreiro, Ana Triguero, Lalita Banerjee, Andrew McMillan, Erlene Seymour, Jamie Hirata, Jayson de Guzman, Sunil Sharma, Hyun Yong Jin, Lisa Musick, Catherine Diefenbach
Background Diffuse large B-cell lymphoma comprises nearly 30% of non-Hodgkin lymphoma cases and patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for stem-cell transplantation have few treatment options and poor prognoses. We aimed to determine whether the novel combination of polatuzumab vedotin in combination with rituximab and lenalidomide (Pola+R+Len) would provide
-
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation Lancet Haematol. (IF 24.7) Pub Date : 2024-01-03 Olaf Penack, Monia Marchetti, Mahmoud Aljurf, Mutlu Arat, Francesca Bonifazi, Rafael F Duarte, Sebastian Giebel, Hildegard Greinix, Mette D Hazenberg, Nicolaus Kröger, Stephan Mielke, Mohamad Mohty, Arnon Nagler, Jakob Passweg, Francesca Patriarca, Tapani Ruutu, Hélène Schoemans, Carlos Solano, Radovan Vrhovac, Daniel Wolff, Zinaida Peric
Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic haematopoietic stem-cell transplantation (HSCT). In the last 3 years, there has been regulatory approval of new drugs and considerable change in clinical approaches to prophylaxis and management of GVHD. To standardise treatment approaches, the European Society for Blood and Marrow Transplantation
-
Correction to Lancet Haematol 2023; 10: e713–34 Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20
Abstract not available
-
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Haematol. (IF 24.7) Pub Date : 2023-12-21 Domenico Russo, Michael Schmitt, Sylvain Pilorge, Matthias Stelljes, Toshiro Kawakita, Valerie L Teal, Barbara Haber, Charlene Bopp, Sanjeet S Dadwal, Cyrus Badshah
Background In a pivotal phase 3 trial of cytomegalovirus prophylaxis with letermovir for up to 100 days after allogeneic haematopoietic stem-cell transplantation (HSCT), 12% of participants developed clinically significant cytomegalovirus infection after letermovir was discontinued. We aimed to evaluate the efficacy and safety of extending the duration of letermovir prophylaxis for clinically significant
-
Extended duration of letermovir prophylaxis: how long is long enough? Lancet Haematol. (IF 24.7) Pub Date : 2023-12-21 Abby P Douglas, Monica A Slavin
Abstract not available
-
2023 ASH Annual Meeting Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Emma Cookson
Abstract not available
-
Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Catherine Cargo MB PhD, Elsa Bernard PhD, Tumas Beinortas MB, Kelly L Bolton MD, Paul Glover MSc, Helen Warren MSc, Daniel Payne PhD, Rukhsaar Ali MSc, Alesia Khan MB, Mike Short BSc, Suzan Van Hoppe MSc, Prof Alex Smith PhD, Jan Taylor PhD, Paul Evans PhD, Elli Papaemmanuil PhD, Simon Crouch PhD
Somatic mutations are frequently reported in individuals with cytopenia but without a confirmed haematological diagnosis (clonal cytopenia of undetermined significance; CCUS). These patients have an increased risk of progression to a myeloid malignancy and worse overall survival than those with no such mutations. To date, studies have been limited by retrospective analysis or small patient numbers
-
The dawn of the CRISPR/Cas9 gene therapy era Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 The Lancet Haematology
Abstract not available
-
Oral decitabine plus cedazuridine versus intravenous decitabine Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Theo de Witte
Abstract not available
-
Predicting the progression of patients with CCUS to myeloid neoplasia Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Emma M Groarke
Abstract not available
-
Changing the paradigm of AML care in India Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Amitabh Singh, Ankur Jain, Heena Tabbassum, Fouzia Siraj, Bhavika Rishi, Aroonima Misra
Abstract not available
-
Lucrèce Delicat-Loembet: offering hope to young people with sickle cell disease Lancet Haematol. (IF 24.7) Pub Date : 2023-12-20 Tony Kirby
Abstract not available